ArticleCureus2026
Diagnostic Utility of PRAME and SOX10 Immunostaining for Vulvar Melanocytic Lesions.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVulvar melanoma (VM) is a rare type of malignant melanoma. Clinical presentations typically show mass or bleeding. Benign melanocytic lesions of the vulva include genital lentigines and genital melanocytic nevus. SOX10 is a marker commonly used in melanocytic lesions, and the preferentially expressed antigen in melanoma (PRAME) is a recent marker that shows high specificity for malignant melanoma.
objectivesThe study is to evaluate the histopathology and immunohistochemistry of SOX10 and PRAME in VM and benign vulvar melanocytic lesions (genital lentigine and genital melanocytic nevus). MATERIALS AND
methodsAll cases of VM and benign vulvar melanocytic lesions were recruited. Clinical and pathological data were reviewed. SOX10 and PRAME immunohistochemistry were performed and compared between VM and benign vulvar melanocytic lesions.
resultsOf the total nine cases with VM, 6 (66.7%) presented with mass, 2 (22.2%) had mass with bleeding, and one (11.1%) developed urinary discomfort. Histopathologically, mucosal lentiginous melanoma is the most common subtype. Thirteen cases with benign melanocytic lesions were found. In immunohistochemical studies, SOX10 showed positivity in all 9 (100%) VM and all 13 (100%) benign melanocytic lesions. PRAME showed positivity in 7 (77.8%) cases. All 13 (100%) benign melanocytic lesions show negative stains for PRAME. The sensitivity of SOX10 and PRAME in the diagnosis of VM was 100% and 88.9%, respectively. The specificity of SOX10 and PRAME in the diagnosis of VM was 0% and 100%, respectively.
conclusionsSOX10 and PRAME are nuclear staining markers that can be used for diagnostic purposes and as adjunct markers for the diagnosis of VM and benign melanocytic lesions. PRAME immunostaining shows high specificity for melanoma and melanoma in situ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.